TY - JOUR
T1 - Motor Fluctuations Development Is Associated with Non-Mostor Symptoms Burden Progression in Parkinson's Disease Patients :
T2 - A 2-Year Follow-Up Study
AU - Santos García, Diego
AU - de Deus Fonticoba, Teresa
AU - Cores Bartolomé, Carlos
AU - Feal Painceiras, Maria J.
AU - Suárez Castro, Ester
AU - Canfield Medina, H.
AU - Martínez Miró, Cristina
AU - Jesús, Silvia
AU - Aguilar Barberà, Miquel
AU - Pastor, Pau
AU - Planellas, Lluis
AU - Cosgaya, Marina
AU - García Caldentey, Juan
AU - Caballol, Nuria
AU - Legarda, Inés
AU - Hernández-Vara, Jorge
AU - Cabo-Lopez, Iria
AU - López Manzanares, Lydia
AU - Gonzalez-Aramburu, Isabel
AU - Ávila Rivera, M.A.
AU - Gómez Mayordomo, Víctor
AU - Nogueira, Víctor
AU - Puente, Víctor
AU - Dotor García-Soto, Julio
AU - Borrué, Carmen
AU - Solano Vila, Berta
AU - Álvarez Sauco, María
AU - Vela, Lydia
AU - Escalante, Sonia
AU - Cubo, Esther
AU - Carrillo Padilla, Francisco
AU - Martínez-Castrillo, Juan Carlos
AU - Sánchez Alonso, Pilar
AU - Alonso Losada, Maria G.
AU - López Ariztegui, Nuria
AU - Gastón, Itziar
AU - Kulisevsky, Jaime
AU - Blázquez Estrada, Marta
AU - Seijo, Manuel
AU - Ruiz Martínez, Javier
AU - Valero, Caridad
AU - Kurtis, Mónica
AU - Fàbregues-Boixar i Nebot, Oriol de
AU - González Ardura, Jessica
AU - Alonso Redondo, Ruben
AU - Ordás, Carlos
AU - López Díaz, Luis M.
AU - McAfee, Darrian
AU - Martinez-Martin, Pablo
AU - Mir, Pablo
AU - Santacruz, Pilar
AU - Pascual-Sedano, Berta María
AU - Pagonabarraga Mora, Javier
AU - Martí, Maria José
AU - Martí-Andres, Gloria
AU - Lucas-del-Pozo, Sara
AU - Horta Barba, Andrea
AU - Crespo Cuevas, Ane Miren
AU - Cámara Lorenzo, Ana
AU - Bejr-kasem, Helena
PY - 2022
Y1 - 2022
N2 - The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson's disease (PD) patients regarding the development of motor fluctuations (MF). PD patients without MF at baseline, who were recruited from January 2016 to November 2017 (V0) and evaluated again at a 2-year follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this analysis. MF development at V2 was defined as a score ≥ 1 in the item-39 of the UPDRS-Part IV, whereas NMS burden was defined according to the Non-motor Symptoms Scale (NMSS) total score. Three hundred and thirty PD patients (62.67 ± 8.7 years old; 58.8% males) were included. From V0 to V2, 27.6% of the patients developed MF. The mean NMSS total score at baseline was higher in those patients who developed MF after the 2-year follow-up (46.34 ± 36.48 vs. 34.3 ± 29.07; p = 0.001). A greater increase in the NMSS total score from V0 to V2 was observed in patients who developed MF (+16.07 ± 37.37) compared to those who did not develop MF (+6.2 ± 25.8) (p = 0.021). Development of MF after a 2-year follow-up was associated with an increase in the NMSS total score (β = 0.128; p = 0.046) after adjustment to age, gender, years from symptoms onset, levodopa equivalent daily dose (LEDD) and the NMSS total score at baseline, and the change in LEDD from V0 to V2. In PD patients, the development of MF is associated with a greater increase in the NMS burden after a 2-year follow-up.
AB - The aim of the present study was to analyze the progression of non-motor symptoms (NMS) burden in Parkinson's disease (PD) patients regarding the development of motor fluctuations (MF). PD patients without MF at baseline, who were recruited from January 2016 to November 2017 (V0) and evaluated again at a 2-year follow-up (V2) from 35 centers of Spain from the COPPADIS cohort, were included in this analysis. MF development at V2 was defined as a score ≥ 1 in the item-39 of the UPDRS-Part IV, whereas NMS burden was defined according to the Non-motor Symptoms Scale (NMSS) total score. Three hundred and thirty PD patients (62.67 ± 8.7 years old; 58.8% males) were included. From V0 to V2, 27.6% of the patients developed MF. The mean NMSS total score at baseline was higher in those patients who developed MF after the 2-year follow-up (46.34 ± 36.48 vs. 34.3 ± 29.07; p = 0.001). A greater increase in the NMSS total score from V0 to V2 was observed in patients who developed MF (+16.07 ± 37.37) compared to those who did not develop MF (+6.2 ± 25.8) (p = 0.021). Development of MF after a 2-year follow-up was associated with an increase in the NMSS total score (β = 0.128; p = 0.046) after adjustment to age, gender, years from symptoms onset, levodopa equivalent daily dose (LEDD) and the NMSS total score at baseline, and the change in LEDD from V0 to V2. In PD patients, the development of MF is associated with a greater increase in the NMS burden after a 2-year follow-up.
KW - Parkinson's disease
KW - Burden
KW - Follow-up
KW - Motor fluctuations
KW - Non-motor symptoms
U2 - 10.3390/diagnostics12051147
DO - 10.3390/diagnostics12051147
M3 - Article
C2 - 35626303
SN - 2075-4418
VL - 12
JO - Diagnostics
JF - Diagnostics
IS - 5
ER -